EyePoint Pharmaceuticals, Inc. - stock earnings
EYPT Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 BeforeMarket | -0.33 / -0.41 | - | - / 10.1 million | - |
EYPT Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -14.1 million USD | 14.0 million USD |
| 2023Q3 | -12.6 million USD | 15.2 million USD |
| 2023Q2 | -22.9 million USD | 9.1 million USD |
| 2023Q1 | -21.6 million USD | 7.7 million USD |
| 2022Q4 | -64.2 million USD | 10.5 million USD |
| 2022Q3 | -18.4 million USD | 10.0 million USD |
| 2022Q2 | -19.6 million USD | 11.6 million USD |
| 2022Q1 | -22.5 million USD | 9.3 million USD |
| 2021Q4 | -19.4 million USD | 11.5 million USD |
| 2021Q3 | -16.7 million USD | 9.1 million USD |
| 2021Q2 | -10.0 million USD | 9.0 million USD |
| 2021Q1 | -12.3 million USD | 7.3 million USD |
| 2020Q4 | -15.5 million USD | 7.1 million USD |
| 2020Q3 | -3.8 million USD | 15.7 million USD |
| 2020Q2 | -13.0 million USD | 4.1 million USD |
| 2020Q1 | -13.2 million USD | 7.5 million USD |
| 2019Q4 | -10.4 million USD | 8.6 million USD |
| 2019Q3 | -15.6 million USD | 2.5 million USD |
| 2019Q2 | -11.5 million USD | 7.2 million USD |
| 2019Q1 | -19.2 million USD | 2.0 million USD |
| 2018Q4 | -11.6 million USD | 2.4 million USD |
| 2018Q3 | -33.1 million USD | 486000 USD |
| 2018Q2 | -34.4 million USD | 715000 USD |
| 2018Q1 | -7.0 million USD | 928000 USD |
| 2017Q4 | -5.8 million USD | 933000 USD |
| 2017Q3 | -6.0 million USD | 385000 USD |
| 2017Q2 | -6.1 million USD | 701000 USD |
| 2017Q1 | -5.1 million USD | 590000 USD |
| 2016Q4 | -67000 USD | 6.0 million USD |
| 2016Q3 | -7.2 million USD | 277000 USD |
| 2016Q2 | -6.4 million USD | 304000 USD |
| 2016Q1 | -5.0 million USD | 324000 USD |
| 2015Q4 | -5.2 million USD | 526000 USD |
| 2015Q3 | -4.9 million USD | 466000 USD |
| 2015Q2 | -5.1 million USD | 409000 USD |
| 2015Q1 | -5.0 million USD | 328000 USD |
| 2014Q4 | -4.1 million USD | 521000 USD |
| 2014Q3 | 20.6 million USD | 25.3 million USD |
| 2014Q2 | -4.0 million USD | 292000 USD |
| 2014Q1 | -2.2 million USD | 2.0 million USD |
| 2013Q4 | -3.5 million USD | 592000 USD |
| 2013Q3 | -3.7 million USD | 597000 USD |
| 2013Q2 | -3.9 million USD | 492000 USD |
| 2013Q1 | -2.8 million USD | 513000 USD |
| 2012Q4 | -2.6 million USD | 585000 USD |
| 2012Q3 | -2.6 million USD | 553000 USD |
| 2012Q2 | -2.3 million USD | 699000 USD |
| 2012Q1 | -2.7 million USD | 538000 USD |
| 2011Q4 | -17.5 million USD | 630000 USD |
| 2011Q3 | -2.4 million USD | 1.7 million USD |
| 2011Q2 | -140000 USD | 3.7 million USD |
| 2011Q1 | -2.7 million USD | 360000 USD |
| 2010Q4 | -2.7 million USD | 414000 USD |
| 2010Q3 | -3.1 million USD | 476000 USD |
| 2010Q2 | 13.1 million USD | 15.7 million USD |
| 2010Q1 | -2.7 million USD | 515000 USD |
| 2009Q4 | -24000 USD | 3.4 million USD |
| 2009Q3 | -1.6 million USD | 3.4 million USD |
| 2009Q2 | -534000 USD | 3.2 million USD |
| 2009Q1 | -636000 USD | 3.2 million USD |
| 2008Q4 | -870000 USD | 3.0 million USD |
| 2008Q3 | -471000 USD | 2.8 million USD |
| 2008Q2 | -63.6 million USD | 2.7 million USD |
| 2008Q1 | -5.5 million USD | 542000 USD |
| 2007Q4 | -5.8 million USD | 128000 USD |
| 2007Q3 | -13.4 million USD | 455000 USD |
| 2007Q2 | -13.4 million USD | 455000 USD |
| 2007Q1 | -8.7 million USD | 65000 USD |
| 2006Q4 | -39.8 million USD | 837188 USD |
| 2006Q3 | -4.0 million USD | 409717 USD |
| 2006Q2 | -6.0 million USD | 375120 USD |
| 2006Q1 | -5.6 million USD | 351902 USD |
| 2005Q4 | -2.6 million USD | 148429 USD |
| 2005Q3 | -5.8 million USD | 670706 USD |
| 2005Q2 | -2.6 million USD | 148429 USD |
| 2005Q1 | -2.8 million USD | 160365 USD |
| 2004Q4 | -2.9 million USD | 161816 USD |
| 2004Q3 | -2.7 million USD | 150749 USD |
| 2004Q2 | -450088 USD | 46641 USD |
| 2004Q1 | -703124 USD | 72863 USD |
| 2003Q4 | -692811 USD | 71794 USD |
| 2003Q3 | -626237 USD | 64895 USD |
| 2003Q2 | -603772 USD | 24165 USD |
| 2003Q1 | -417953 USD | 16729 USD |
| 2002Q4 | -387813 USD | 15522 USD |
| 2002Q3 | -375369 USD | 15024 USD |
EYPT Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -70.8 million USD | 46.0 million USD |
| 2022 | -124.5 million USD | 41.4 million USD |
| 2021 | -63.9 million USD | 36.9 million USD |
| 2020 | -52.7 million USD | 34.4 million USD |
| 2019 | -63.0 million USD | 20.4 million USD |
| 2018 | -53.2 million USD | 3.0 million USD |
| 2017 | -18.5 million USD | 7.5 million USD |
| 2016 | -21.5 million USD | 1.6 million USD |
| 2015 | 6.3 million USD | 26.6 million USD |
| 2014 | -13.4 million USD | 3.5 million USD |
| 2013 | -11.9 million USD | 2.1 million USD |
| 2012 | -24.8 million USD | 3.5 million USD |
| 2011 | -8.6 million USD | 5.0 million USD |
| 2010 | 8.8 million USD | 23.1 million USD |
| 2009 | -2.5 million USD | 12.2 million USD |
| 2008 | -75.7 million USD | 3.5 million USD |
| 2007 | -103.7 million USD | 2.2 million USD |
| 2006 | -20.9 million USD | 1.5 million USD |
| 2005 | -11.2 million USD | 629524 USD |
| 2004 | -11.2 million USD | 629524 USD |
| 2003 | -2.6 million USD | 265229 USD |
| 2002 | -1.9 million USD | 74351 USD |
| 2001 | -2.3 million USD | 516321 USD |
EYPT
Price: $19.74
52 week price:
Earnings Per Share: -1.82 USD
P/E Ratio: -11.14
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 166382
Market Capitalization: 1.0 billion